Interferon signaling patterns in peripheral blood lymphocytes may predict clinical outcome after high-dose interferon therapy in melanoma patients

Diana L Simons1, Gerald Lee1, John M Kirkwood2* and Peter P Lee1*

Abstract

Background: High-dose Interferon (HDI) therapy produces a clinical response and achieves relapse-free survival in 20-33% of patients with operable high risk or metastatic melanoma. However, patients may develop significant side effects frequently necessitating dose reduction or discontinuation of therapy. We recently showed that peripheral blood lymphocytes (PBL) from some melanoma patients have impaired interferon (IFN) signaling which could be restored with high concentrations of IFN. This exploratory study evaluated IFN signaling in PBL of melanoma patients to assess whether the restoration of PBL IFN signaling may predict a beneficial effect for HDI in melanoma patients.

Methods: PBL from 14 melanoma patients harvested on Day 0 and Day 29 of neoadjuvant HDI induction therapy were analyzed using phosflow to assess their interferon signaling patterns through IFN-α induced phosphorylation of STAT1-Y701.

Results: Patients who had a clinical response to HDI showed a lower PBL interferon signaling capacity than non-responders at baseline (Day 0). Additionally, clinical responders and patients with good long-term outcome showed a significant increase in their PBL interferon signaling from Day 0 to Day 29 compared to clinical non-responders and patients that developed metastatic disease. The differences in STAT1 activation from pre- to post-HDI treatment could distinguish between patients who were inclined to have a favorable or unfavorable outcome.

Conclusion: While the sample size is small, these results suggest that interferon signaling patterns in PBL correlate with clinical responses and may predict clinical outcome after HDI in patients with melanoma. A larger confirmatory study is warranted, which may yield a novel approach to select patients for HDI therapy.

Keywords: Melanoma High-Dose Interferon, Lymphocyte Signaling, STAT1
correspond with the autoimmune effects induced by IFN therapy.

We recently showed that peripheral blood lymphocytes (PBL) from patients with melanoma and other cancers have reduced phosphorylation of signal transducer and activators of transcription 1 (pSTAT1) upon Interferon-α (IFN-α) stimulation, demonstrating a defect in Type I IFN signaling [15,16]. Moreover, such defects could be partially restored by prolonged stimulation with IFN [15]. This offered a possible mechanism for the beneficial effect of HDI therapy in melanoma patients, and also suggested a way to select patients for therapy based on their PBL IFN signaling patterns.

Type I IFNs (α/β) have been recognized to have important and diverse immunoregulatory functions. These include promoting proliferation and clonal expansion of CD4 and CD8 T cells [17-20], enhancing antibody production of B cells [21,22], and increasing cytotoxic activity of natural killer cells (NK) and CD8 T cells [23,24]. IFN also has negative effects on the activation and proliferation of T regulatory cells (Tregs) [25], which are known for their immunosuppressive roles in cancer. With the advancement of flow cytometry-based assays, signaling profiles of immune cells can be measured with increased sensitivity through phospho-flow (phosflow) analysis, which provides the ability to concurrently measure signaling activities within multiple cell types.

In the present study, we measured IFN signaling responses in peripheral blood lymphocytes from stage IIIB-C melanoma patients taken before treatment and at day 29 of neo-adjuvant HDI therapy. In addition, all of these patients continued on a maintenance regimen of HDI post surgical resection. Archived peripheral blood mononuclear cells (PBMCs) were assessed using phosflow to measure Type I IFN signaling responses through IFN-α-induced phosphorylation of STAT1-Y701 in patients undergoing HDI therapy with known short-term clinical responses and long-term clinical outcome. This exploratory study found that there was a correlation in PBL T cells between response to IFN-α-induced STAT1 activation and clinical responses during the induction phase of HDI. Moreover, we were able to correlate STAT1 activation in T cells from HDI treated melanoma patients over the 4-week induction phase to clinical outcome, demonstrating that measuring the IFN signaling patterns in peripheral blood lymphocytes may be useful to select patients who are more likely to benefit from HDI maintenance therapy.

Methods

Patient Characteristics

Archived peripheral blood mononuclear cells (PBMCs) from 14 Stage IIIB-C melanoma patients (a total of 28 PBMC samples, 14 acquired pre- and 14 acquired post-HDI treatment) were analyzed for STAT1-Y701 phosphorylation (pSTAT1) levels by phosflow cytometry. Patient demographics and clinical details are shown in Table 1.

These patients participated in a clinical trial for neoadjuvant therapy with HDI and their treatment has been thoroughly described [12]. Briefly, the HDI induction phase consisted of IFN-α2b 20 million units (MU)/m² per day intravenously, 5 days per week (Monday to Friday) for 4 weeks. Following surgical resection, patients were placed on a HDI maintenance regimen of

Table 1 Patient characteristics and clinical outcome of HDI treated melanoma patients

| Patient ID | Age (y) | Gender | Clinical Response | Status at Follow-up | HDI Completed | Duration of Disease Free (mo) | Current status |
|------------|---------|--------|-------------------|---------------------|--------------|-------------------------------|---------------|
| 890        | 50      | M      | CR                | MET                 | Y, DR        | 32                            | Deceased      |
| 901        | 62      | F      | NR                | MET                 | Y            | 2                             | Deceased      |
| 903        | 45      | M      | PR                | NED                 | Y            | 86                            | Alive         |
| 973        | 59      | M      | PR                | NED                 | Y            | 54                            | Alive         |
| 974        | 70      | F      | NR                | NED                 | Y, DRx2      | 67                            | Alive         |
| 978        | 75      | M      | PR                | MET                 | Y            | 12                            | Deceased      |
| 980        | 56      | F      | NR                | MET                 | Y, DRx2      | 6                             | Deceased      |
| 983        | 45      | M      | NR                | MET                 | Y            | 6                             | Deceased      |
| 985        | 76      | F      | PR                | NED                 | Y, DR        | 65                            | Alive         |
| 1006       | 78      | M      | PR                | MET                 | Y            | 6                             | Deceased      |
| 1008       | 49      | M      | PR                | NED                 | Y, DR        | 61                            | Alive         |
| 1015       | 57      | F      | PR                | MET                 | Y            | 4                             | Deceased      |
| 1018       | 44      | M      | PR                | NED                 | Y            | 60                            | Alive         |
| 1052       | 54      | M      | NR                | MET                 | Y            | 19                            | Alive         |

NOTE: Adapted from ref.[12]

*Age at time of last contact.

HDI: High Dose IFN-α2b; CR: Complete Response; PR: Partial Response; NR: No Response; MET: Metastasis; NED: No Evidence of Disease; DR: Dose Reduction; DRx2: Two Dose Reductions
consisting of IFN-α2b 10 MU/m² per day subcutaneously, three times per week (Monday, Wednesday, Friday) for 48 weeks. For each patient, blood samples were taken before (Day 0-pre) and after the 4-week induction phase of HDI (Day 29-post). Due to adverse events, 5 patients underwent 1/3 dose reductions and two of these patients required dose reductions twice (Table 1). Phosphorylated STAT1 levels were measured in lymphocytes, T cell subsets (both CD4 and CD8) and B cells with or without stimulation of IFN-α for each of these two time points. All patients signed informed consent and the study was approved by the University of Pittsburgh (Pittsburgh, PA) Institutional Review Board.

Interim responses were determined using WHO criteria [26] and patients were classified as clinical responders or non-responders based on a measure of tumor reduction both clinically and histologically over the 4-week induction phase of HDI therapy [12]. Among these patients, 9 showed a complete response (n = 1) or partial response (n = 8) and both were grouped into a single responder group (R). Five patients did not exhibit a clinical response and were grouped as non-responders (NR).

For long-term clinical outcome, patients were further classified as exhibiting no evidence of disease (NED) or metastatic disease (MET) based on their status at the time of follow-up (range 9-86 months) after completing a maintenance regimen of 48 weeks. Six patients were classified as NED and exhibited no evidence of metastases at a minimum follow-up of 4.5 years. In contrast, all of the 8 MET patients developed metastatic disease within 3 years and three of these were disease free for up to 1 year (Table 1).

**IFN-α Stimulation and Detection of pSTAT1-Y701 in HDI-treated Melanoma PBMCs**

IFN-α stimulation and detection of pSTAT1-Y701 in cancer patients have been previously described [16] with modifications. Briefly, cryopreserved PBMCs were thawed and rested overnight in IMDM 10% FBS at 37°C 7% CO₂. Cells were ficollled, resuspended to 2 × 10⁶ cells per 50 μl in IMDM 5% human AB serum (HS) and stained with mouse anti-human CD3 FITC, CD8 PE-Cy7, CD4 PE-AF700 and CD19 PE-TR (Caltag-Invitrogen) for 30 minutes. IMDM 5%HS was added to each tube and 1 × 10⁶ cells were aliquoted per test. PBMCs remained unstimulated or were stimulated with IFN-α (NIAID Reference Reagent Repository) to a final concentration of 1000 IU/ml and incubated at 37°C 7% CO₂ for 15 minutes. Cells were fixed by formalin and incubated at 37°C 7% CO₂ for 10 minutes. PBMCs were washed twice with 1× PBS, resuspended in 1 ml of 1× Custom Perm Buffer (#643435, BD Biosciences), and incubated for 30 minutes at room temperature. Cells were washed in wash buffer (1× PBS, 2% FBS, 0.09% sodium azide), resuspended to exactly 50 μl and incubated with mouse anti-human STAT1-pY701 Alexa Fluor® 647(BD Biosciences) for 1 hour at room temperature. Cells were washed in wash buffer and put on ice until analyzed by flow cytometry on a LSRII flow cytometer (BD Biosciences). Paired pre- and corresponding post- PBMC samples were assayed on the same day.

**Data and Statistical Analysis**

Flow cytometry FCS files were analyzed using FlowJo 8.5.3 (Treestar, http://www.treestar.com). Gating strategy for the selection of lymphocytes, T cells and B cells are shown in Additional File 1 Figure S1. The mean fluorescent intensity (MFI) of STAT1-pY701 Alexa Fluor® 647 was calculated for all stimulated and unstimulated samples and fold changes were determined by dividing the MFI of stimulated samples by the MFI of the responding unstimulated samples. Basal levels of STAT1-Y701 were determined by the MFI in unstimulated cells. Kaplan-Meier survival curves were generated and the correlation of IFN-α induced pSTAT1 with disease-free and overall survival was estimated using the log-rank test. For the purpose of these comparisons, a ratio for each patients’ lymphocytes were determined by dividing the fold change in pSTAT1 post-treatment by the fold change in pSTAT1 pre-treatment. A median of these ratios was generated using all patients in the study (n = 14) and patients were segregated according to whether they fell within a range of ± 0.1 around the median. Data was analyzed using Graphpad Prism 5.00 and the R statistical package 2.7.1 http://www.r-project.org. P-values, estimated differences and 95% confidence intervals were calculated with R software from the Comprehensive R Archive Network using nonparametric unpaired or paired two-sided Wilcoxon-Mann-Whitney T-tests. The False Discovery Rate (FDR) was calculated in R and used to adjust for multiple comparisons testing [27]. Adjusted P-values < 0.05 were considered significant. Coefficient of variations (CV) was calculated by dividing the standard deviation with the mean of the fold changes multiplied by 100.

**Results**

**Differences in IFN responses between clinical responders and non-responders**

Initially, we compared STAT1-Y701 (pSTAT1) activation from patients who underwent IFN dose reductions to patients who did not undergo dose reductions (Table 1 data not shown) before and after the HDI induction phase. Both unpaired and paired analyses showed no significant changes in STAT1 activation between the patients who had dose reductions and patients who did not undergo dose reductions, and from day 0 to day 29 with HDI.
therapy. Subsequently, we addressed whether Type I IFN signaling differed between HDI clinical responders and clinical non-responders at day 0 or day 29 after HDI therapy. The induction of pSTAT1 from IFN-α stimulation was assessed by phosflow in PBMCs by examining the overall median fold change. The median fold change of IFN-α induced pSTAT1 in PBL from responders was lower than non-responders on day 0 (Figure 1A), which was observed in both CD4 and CD8 T cells, but these differences were not statistically significant. In CD19 B cells, a statistically significant difference was observed in the median fold change of pSTAT1 induced by IFN-α in responders and non-responders on day 0 (Figure 1A). The median fold change of pSTAT1 induced by IFN-α in

Figure 1 IFN-α induced fold change of pSTAT1-Y701 in PBMCs from responding and non-responding patients. PBMCs were stimulated with 1000 IU/ml of IFN-α or remained unstimulated and pSTAT1 was assessed by phosflow. The IFN-α induced fold change in pSTAT1 was measured in Lymphocytes, CD4 T cells, CD8 T cells and CD19 B cells. A) Unpaired analysis of PBMCs acquired before and after the 4 week induction phase with HDI were compared between responders (R: pre- open circle, post- open square) and HDI non-responders (NR: pre- closed circle, post- closed square). Two-sided Wilcoxon-Mann-Whitney unpaired analysis was used to compare between responding and non-responding lymphocytes and lymphocyte subsets. (* CD19: p = 0.028, 95% CI: 0.40 to 4.59, CV: pre-R 28.2%, pre-NR 30.9%). B) and C) Paired analysis of HDI responders (R) and HDI non-responders (NR) lymphocytes were assessed for their response to IFN-α through STAT1 activation before (pre-) and after (post-) the 4 week induction phase of HDI therapy. Two-sided Wilcoxon-Mann-Whitney paired analysis was used to compare response levels of pSTAT1 in responding and non-responding melanoma patients. The fold change was calculated by dividing the mean fluorescent intensity (MFI) of stimulated cells by the MFI of unstimulated cells. The median is indicated by the bar in each data set. Adjusted P-values < 0.05 were considered significant. CVs were calculated by dividing the standard deviation with the mean of the fold changes multiplied by 100. (* Lymphocytes: p = 0.039, 95% CI: -3.52 to -0.57, CV: pre-R 25.6%, post-R 30.1%; * CD8: p = 0.039, 95% CI: -5.0 to -0.43, CV: pre-R 19.6%, post-R 29.5%).
lymphocytes and lymphocyte subsets showed little or no difference between responders and non-responders on day 29 (Figure 1A).

Changes in Type I IFN responses from day 0 to day 29 in clinical responders and non-responders
We further investigated within the HDI-responding and non-responding patients on day 0 and day 29 and examined the effect of HDI therapy on Type I IFN signaling. Paired samples from pre-treated HDI PBMCs were compared to lymphocytes from their corresponding post-HDI treated PBMCs in both melanoma responding and non-responding patients. Two-sided Wilcoxon-Mann-Whitney paired analysis demonstrated that there was a statistically significant increase in STAT1 activation after HDI treatment in the responding group, and the response was equally observed in lymphocytes overall and in CD8 T cells (adjusted p-values 0.039, respectively). CD4 T cells were on the cusp of significance (adjusted p-value, 0.052) and B cells showed no significant differences in STAT1 activation (adjusted p-value, 0.30) (Figure 1B). In contrast, there were no significant differences in the response levels within any lymphocyte subset of non-responders from pre- to post-HDI treatment (Figure 1C). To determine whether the overall response was due to the basal levels of pSTAT1, we analyzed changes in pSTAT1 in PBLs in unstimulated cells from before to after HDI treatment. We found no significant differences in the basal expression of pSTAT1 from pre to post HDI treatment in both the responding and non-responding patients (Figure 2A-B).

IFN signaling patterns and clinical outcome
It was observed that disease-free and overall survival was longer amongst patients with a clinical response at day 29 compared with non-responders, although the results did not reach statistical significance [12]. We investigated the association of long-term clinical outcome with IFN-α induced pSTAT1 levels in HDI treated melanoma patient lymphocytes from Day 0 to Day 29. Paired-analysis was used to compare patients who showed no evidence of disease (NED) or who developed subsequent metastatic disease (MET) at the time of clinical follow-up. NED patients demonstrated a significant increase in the activation of STAT1 from Day 0 to Day 29 in lymphocytes and both CD4 and CD8 T cells (adjusted p-values, 0.04 [Figure 3A, Additional File 2 Figure S2]). In contrast, lymphocytes from MET patients did not show a consistent increase in the induction of pSTAT1 from IFN-α stimulation from pre- to post-HDI therapy (Figure 3B).

Since STAT1 activation correlated with long-term clinical outcome, we further examined pSTAT1 responses in lymphocytes with disease-free and overall survival. A ratio for each patient’s lymphocytes was determined by dividing the fold change in pSTAT1 post-treatment by the fold change in pSTAT1 pre-treatment. A median of these ratios (1.25) was generated using all patients in the study (n = 14) and patients were segregated according to whether they fell within a range of ± 0.1 around the median. Patients whose pSTAT1 ratios fell within this range had better disease-free and overall survival (Figure 4A-B, respectively) as compared to patients who had minimal or negative signaling changes (median <1.15), and interestingly, also patients who had larger increases from pre- to post-HDI treatment (median >1.35).

Discussion
Previously, we have demonstrated in two independent cohorts impaired IFN signaling and downstream
functional consequences in PBLs from patients with minimally metastatic stage III and widely metastatic stage IV melanoma as compared to healthy controls [15,16]. In the current study, we analyzed serial PBMC samples obtained from patients before and after the induction phase of HDI in a new independent cohort of minimally metastatic stage IIIb and IIIc melanoma patients to advance our current understanding of immune dysfunction in cancer. This exploratory study demonstrated that patients with high-risk operable nodal involvement with melanoma who had a clinical response to high dose IFN-α2b therapy over the 4-week induction phase of neoadjuvant therapy had a significant increase in STAT1 activation in peripheral blood T cells, but not B cells, upon IFN-α stimulation from Day 0 to Day 29. Moreover, this increase in pSTAT1 in peripheral blood T cells also correlated with good clinical outcome suggesting the efficacy of HDI in the clinical responders may be due, at least in part, to augmentation of their pSTAT1 responsiveness.

Moreover, the differences in STAT1 activation from pre- to post- HDI treatment could distinguish patients who were inclined to have a favorable or unfavorable outcome. As expected, patients who had minimal or negative changes in pSTAT1 (median ratio < 1.15) had poor outcome. Of patients who showed increased pSTAT1 signaling after HDI therapy, only patients who displayed modest augmentation (median ratio 1.15 - 1.35) had good outcome. Interestingly, patients who had 'hyper' IFN signaling responses (median ratio >1.35) of pSTAT1 pre- to post- HDI therapy had poor outcome, similar to those who has minimal or negative changes. These results warrant further confirmation in a larger patient cohort to investigate the underlying mechanisms by which HDI alters IFN signaling patterns in patients with different clinical outcomes.

Assessing the IFN signaling patterns in peripheral blood T cells from melanoma patients from Day 0 to Day 29 HDI therapy may be a clinically useful approach to select patients who would be more inclined to benefit from further treatment, and hence should be maintained on HDI. A trend was observed which showed that responding patients, prior to HDI therapy, have a lower response to IFN-α induced pSTAT1 compared to those of the non-responding patients. We have previously found two subsets of IFN responses in melanoma patients, IFN low-responders and IFN high-responders [15]. We showed that in IFN low-responders, prolonged in vitro stimulation with high doses of IFN partially restored IFN signaling, suggesting a possible mechanism for the beneficial effect of HDI therapy in these melanoma patients. Prior to initiation with HDI (pre), reduced activation of STAT1 in the responding patients compared to the non-responding patients may be explained in that this patient subset exhibited a severe impairment in IFN signaling which was restored during the initiation phase of HDI therapy. In contrast, patients who had higher levels of STAT1 activation prior to the HDI initiation phase may not have had an IFN signaling defect and therefore, would not have benefited from HDI therapy. In our previous study [16], the differences in the median activation of pSTAT1 between melanoma patients and healthy controls were 1.6 fold were as, in the current study, the median differences in STAT1

Figure 3 Correlation of IFN-α induced pSTAT1 and long-term clinical outcome in HDI patients. At the time of clinical follow-up, patients were classified as exhibiting no evidence of disease (NED) or metastases (MET). The IFN-α induced fold change of pSTAT1 in melanoma patients' lymphocytes and lymphocyte subsets were assessed in patients exhibiting A) NED and, B) MET before (pre-) and after (post-) the HDI induction phase: Two-sided paired Wilcoxon-Mann-Whitney tests were performed on melanoma patients pre- and corresponding post- PBMCs and adjusted P-values < 0.05 were considered significant. CVs were calculated by dividing the standard deviation with the mean of the fold changes multiplied by 100. *(lymphocytes: p = 0.042, 95% CI: -3.12 to -0.25, CV: pre-NED 37.4%, post-NED 34%; *CD4: p = 0.042, 95% CI: -4.77 to -0.48, CV: pre-NED 39.6%, post-NED 36.9%; *CD8: p = 0.042, 95% CI: -5.12 to -0.13, CV: pre-NED 30.2%, post-NED 29.9%).
activation between the responders and non-responders was 1.4 fold.

Though B cells showed a significantly lower trend in overall STAT1 activation in responders compared to non-responders before HDI, there was no significant increase in STAT1 activation during the induction phase of HDI in the responding group, and interestingly, non-responders exhibited decreased overall STAT1 activation. It has been reported that subsets of immune cells respond differently to IFNs [28,29] and that in the presence of high amounts of exogenous IFNs, downregulation of the receptors may occur as a negative feedback mechanism [30], thereby reducing responsiveness to IFNs. Additionally, reduced responsiveness in leukocytes may reflect the effects of a high tumor burden whereby tumor cells secreting immunosuppressive cytokines, such as IL-10 and TGF-β, have been shown to induce expression of STAT1 negative regulators such as the suppressors of cytokine signaling (SOCS) proteins and Src homology 2 (SH2)-containing phosphatase-1 and -2 and CD45 [31-33], thereby inhibiting the anti-tumor activity of immune effector cells [34]. Tregs and myeloid-derived suppressor cells, known for their suppressive roles on immune cells [35-37] in cancer, may also contribute to reduced responsiveness to HDI. Altered plasma or serum cytokine profiles in cancer patients [38,39] may predispose peripheral blood leukocytes to impaired IFN signaling.

There was variation and overlap between the responder and non-responder groups. We and others have previously described variation of signaling responses in melanoma patients’ PBMCs using phosflow [15,40,41], suggesting that signaling abnormalities may not arise in all patients, but rather in a subset of patients. Variable responsiveness may explain the small differences observed between the clinical responders and non-responders. The sample size of this study was too small (14 patients) to be conclusive, but these results warrant a larger confirmatory study.

The importance of STAT1 in IFN signaling has been demonstrated in STAT1 knockout mice where STAT1 deficient mice were more likely to develop spontaneous tumors than wild type mice [42], and were more susceptible to viruses and pathogens showing an IFN-dependent link to STAT1 [43]. Previous studies have attempted to link pSTAT1 (and pSTAT3) levels in tumor cells and lymphocytes to clinical outcome of melanoma patients receiving interferon treatment [44,45]. Patients with higher pSTAT1/pSTAT3 ratios in pretreated lymph node biopsy tissues had better clinical outcome [44]; however, these studies did not find a correlation between pSTAT1/pSTAT3 ratios among lymphocytes of regional lymph nodes and survival. One novelty in the present study is to consider pSTAT1 levels in different subsets of peripheral blood lymphocytes.

The use of immune profiles as a prognostic tool to determine melanoma patient survival has been studied, such as using quantification of tumor infiltrating lymphocytes (TILs) in metastatic lesions [46], as well as gene expression profiling of TILs and CD3 T cells from primary cutaneous melanoma where the genes that were
positively associated with survival were mainly related to the immune response [47]. Beyond these prognostic implications, assessing STAT1 activation in PBL of melanoma patients may provide an additional predictive tool to guide the application of HDI therapy.

Conclusion
While the sample size was size, we have found encouraging results which point to measuring STAT1 activation in PBL T cells from Stage IIIB-C melanoma patients to stratify patients according to their potential to benefit from HDI. These results build upon prior studies of patients with advanced melanoma, and warrant confirmatory studies with a larger cohort of melanoma patients who are to receive HDI therapy. This is currently planned in the context of new intergroup studies of HDI. Other agents that enhance IFN signaling in T cells may be developed as novel therapy for melanoma, especially those that do not have the side effects of HDI.

Additional material

Additional file 1: Figure S1. Gating of lymphocytes, T cells and B cells for phosflow analysis. A) Lymphocytes were gated based on their FSC and SSC properties. B) Within the lymphocyte gate, B cells were selected by gating on CD19+CD3- events and T cells were selected by gating on CD3+CD19- events. C) T cells were further divided into CD4+CD8-T helper cells and CD4-CD8+ cytotoxic T cells. D) Phosphorylation of STAT1-Y701 is demonstrated in stimulated cells (blue line) versus unstimulated cells (red line).

Additional file 2: Figure S2. IFN-induced pSTAT1 expression in lymphocytes. Histogram overlays were generated for unstimulated (thin grey line) and IFN-as stimulated (bold black line) lymphocytes for A) NED and B) MET patients before HDI therapy (open histograms) and after (shaded histograms) 29 days with HDI therapy. * Indicates melanoma patients that were clinical non-responders. CVs were calculated by dividing the standard deviation with the mean of the fold changes multiplied by 100. CV: pre-NED 37.4%, post-NED 34%, pre-MET 21.8%, post-MET 31.5%.

Acknowledgements and Funding
We thank Dr. Skip Maino and Maria Suni (BD Biosciences, San Jose, CA) for helpful advice and the Custom Perm Buffer for phosflow. We thank Ning Yan, Andrea Miyahira, Neta Zuckerman, and Hongxiang Yu for their insightful contribution to the manuscript. We thank Cindy Sander for her technical assistance. This work was in part supported by Award Number P50CA121973 from the National Cancer Institute. This work was supported at the UPCI by the P50 SPORE in Skin Cancer 121973 from the National Cancer Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute or the National Institutes of Health.

Author details
1Dept. of Medicine, Stanford University, Stanford, CA, USA. 2Dept. of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.

Authors’ contributions
PL and JK designed the study. JK provided the clinical samples. DS and GL carried out the experiments. DS, GL, JK, and PL analyzed the results, and wrote the manuscript. All authors read and approved the final manuscript.

Competing interests
The authors declare that they have no competing interests.

Received: 9 February 2011 Accepted: 5 May 2011 Published: 5 May 2011

References
1. Tarhini AA, Kirkwood JM: Clinical and immunologic basis of interferon therapy in melanoma. Ann N Y Acad Sci 2009, 1182:47-57.
2. Elaesser-Beile U, Drees N, Neumann HA, Schopf E: Phase II trial of recombinant leukocyte A interferon in advanced malignant melanoma. J Cancer Res Clin Oncol 1987, 113:273-278.
3. Creagan ET, Schaid DJ, Ahmann DL, Frytak S: Recombinant interferons in the management of advanced malignant melanoma. Updated review of five prospective clinical trials and long-term responders. Am J Clin Oncol 1988, 11:652-659.
4. Kirkwood JM, Manola J, Ibrahim J, Sondak V, Ernstoff MS, Rao U: A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res 2004, 10:1670-1677.
5. Wheelate K, Ives N, Hancock B, Gore M, Eggermont AM, Suciu S: Does interferon-adjuvant-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials. Cancer Treat Rev 2003, 29:241-252.
6. Pirard D, Heenen M, Melot C, Vereecken P: Interferon alpha as adjuvant post-surgical treatment of melanoma: a meta-analysis. Dermatology 2004, 208:43-48.
7. Mitchell MS, Abrams J, Thompson JA, Kashani-Sabet M, DeConti RC, Hwu WJ, Atkins MB, Whittman E, Ernstoff MS, Hakusku FG, et al: Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon Alfa-2b compared with high-dose interferon Alfa-2b for Resected stage III cutaneous melanoma. J Clin Oncol 2007, 25:2076-2085.
8. Pectasides D, Dafni U, Bafaloukos D, Skarlos D, Polyzos A, Tsoutsos D, Kalofonos H, Fotoulias G, Panagiotopoulo P, Kokkalis G, et al: Randomized phase III study of 1 month versus 1 year of adjuvant high-dose interferon alfa-2b in patients with resected high-risk melanoma. J Clin Oncol 2009, 27:939-944.
9. Mocellin S, Pasquali S, Rossi CR, Nitti D: Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis. J Natl Cancer Inst 2010, 102:493-501.
10. Dvorak HF, Gresser I: Microward injury in pathogenesis of interferon-induced necrosis of subcutaneous tumors in mice. J Natl Cancer Inst 1989, 81:497-502.
11. Thyrell L, Eriksson S, Zhivotovsky B, Pokrovskaya K, Sangfelt O, Castro J, Einhorn S, Grander D: Mechanisms of Interferon-alpha induced apoptosis in malignant cells. Oncogene 2002, 21:1251-1262.
12. Moschos SJ, Edington HD, Land SR, Rao UN, Juck D, Shippe-Spotter J, Kirkwood JM: Neoadjuvant treatment of regional stage IIIIB melanomas with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses. J Clin Oncol 2006, 24:3164-3171.
13. Gogas H, Ioannovich J, Dafni U, Stavropoulou-Giokas C, Frangia K, Tsoutsos D, Panagiotopoulo G, Frangia K, Tsoutsos D, Papadopoulos O, Stratigos A, et al: Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 2006, 354:709-718.
14. Yunkovetsky ZR, Kirkwood JM, Edington HD, Marangoni AM, Velokblathayana I, Winans MT, Gorelik E, Lokshin AE: Multiplex analysis of serum cytokines in melanoma patients treated with interferon-alpha2b. Clin Cancer Res 2007, 13:2422-2428.
15. Critchley-Thorne RJ, Yan N, Nacu S, Weber J, Holmes SP, Lee PP: Down-regulation of the interferon signalling pathway in T lymphocytes from patients with metastatic melanoma. PLoS Med 2007, 4:e176.
16. Critchley-Thorne RJ, Simons DL, Yan N, Miyahira AK, Debas FM, Johnson DL, Swetter SM, Carlson RW, Fisher GA, Koong A, et al: Impaired interferon signaling is a common immune defect in human cancer. Proc Natl Acad Sci USA 2009, 106:9010-9015.
17. Dondi E, Roue G, Yuste VJ, Susin SA, Pellegrini S: A dual role of IFN-alpha in the balance between proliferation and death of human CD4+ T lymphocytes during primary response. J Immunol 2004, 173:3740-3747.
18. Havenar-Daughton C, Komanam GA, Murali-Krishna K, Cutting Edge: The direct action of type I IFN on CD4 T cells is crucial for sustaining clonal
expansion in response to a viral but not a bacterial infection. J Immunol 2006, 176:3313-3319.

19. Curtiss JM, Valenzuela JO, Agarwal P, Lins D, Mescher MF: Type I IFNs provide a third signal to CD8 T cells to stimulate clonal expansion and differentiation. J Immunol 2005, 174:4465-4469.

20. Kolumban GA, Thomas S, Thompson LJ, Sprent J, Murali-Krishna K: Type I interferons act directly on CD8 T cells to allow clonal expansion and memory formation in response to viral infection. J Exp Med 2005, 202:637-650.

21. Le Bon A, Thompson C, Kamphuis E, Durand V, Rossmann C, Kalinke U, Tough DR: Cutting edge: enhancement of antibody responses through direct stimulation of B and T cells by type I IFNs. J Immunol 2006, 176:2074-2078.

22. Giordani L, Sanchez M, Libri I, Quaranta MG, Mattioli B, Viora M: IFN-alpha amplifies human naive B cell TLR-9-mediated activation and Ig production. J Leukoc Biol 2009, 86:261-271.

23. Jewett A, Bonavida B: Interferon-alpha activates cytotoxic function but inhibits interleukin-2-mediated proliferation and tumor necrosis factor-alpha secretion by immature human killer cells. J Clin Immunol 1995, 15:35-44.

24. Bose A, Baral R: IFNalpha2b stimulated release of IFNgamma differentially regulates T cell and NK cell mediated tumor cell cytotoxicity. Immunol Lett 2007, 108:65-72.

25. Goldberg A, Rosen A, Petri M, Akhter E, Andrade F: Interferon-alpha and interferon gamma- induced genes by suppressing transduction, gene expression, and antitumor activity of immune effector cells are negatively regulated by suppressor of cytokine signaling protein. J Immunol 2003, 169:9706-9717.

26. Miller AB, Hoogstraten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer 1981, 47:207-214.

27. Benjamini Y, Yekutieli D: Y: The control of the false discovery rate in multiple testing under dependency. Annals of Statistics 2001, 29:1165-1188.

28. Waddell SJ, Popper SJ, Rubins KH, Griffiths MJ, Brown PO, Levin M, Relman DA: Dissecting interferon-induced transcriptional programs in human peripheral blood cells. PLoS One 2010, 5:e9753.

29. van Boeckel-Dezaire AH, Zola JA, Xu Y, Ransohoff RM, Jacobberger JW, Stark GR: Major Differences in the Responses of Primary Human Leukocyte Subsets to IFN-beta. J Immunol 2010, 185:5888-5899.

30. Tchizawa S, Akamatsu S, Sugiyama Y, Muraguchi M, Ohmoto Y, Ono Y, Ishikawa H, Tanigami A, Sumida T, Mori T: A flow cytometric method for determination of the interferon receptor IFNAR2 subunit in peripheral blood leukocyte subsets. J Pharmacol Toxicol Methods 2004, 50:59-66.

31. Ito S, Ansari P, Sakatsume M, Kalinke U, Tough DR: Interleukin-10 inhibits expression of both interferon alpha- and interferon gamma-induced genes by suppressing tyrosine phosphorylation of STAT1. Blood 1999, 93:1456-1463.

32. Park IK, Shultz LD, Lettenio JJ, Goihm JD: TGF-beta1 Inhibits T-bet induction by IFN-gamma in murine CD4+ T cells through the protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-1. J Immunol 2005, 175:5666-5674.

33. Fox SW, Haque SJ, Lovibond AC, Chambers TJ: The possible role of TGF-beta-induced suppressors of cytokine signaling expression in osteoclast/macrophage lineage commitment in vitro. J Immunol 2003, 170:3679-3687.

34. Zimmerer JM, Leisinski GB, Kondadasala SV, Karpa VI, Lehman A, Raychaudhury A, Becknell B, Canon WE: IFN-alpha-induced signal transduction, gene expression, and antitumor activity of immune effector cells are negatively regulated by suppressor of cytokine signaling proteins. J Immunol 2007, 178:4832-4845.

35. Vignuer M, Lemaitre F, Verola O, Cho MS, Gorochov G, Dubernet L, Bachelez H, Kouriulis P, Ferradini L, Foxp3 expressing CD4+CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol 2004, 173:1444-1453.

36. Serafin P, Borello I, Bronte V: Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Semin Cancer Biol 2005, 16:53-65.

37. Mango I, Dolcetti L, Serafin P, Zanovello P, Bronte V: Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. Immuno Rev 2008, 222:162-179.

38. Krasagakis K, Tholke D, Farthmann B, Eberle J, Mansmann U, Orfanos CE: Elevated plasma levels of transforming growth factor (TGF)-beta1 and TGF-beta2 in patients with disseminated malignant melanoma. Br J Cancer 1998, 77:1492-1494.

39. Saito H, Tsutjani S, Oka S, Kondo A, Ikeguchi M, Maeta M, Kaibara N: An elevated serum level of transforming growth factor-beta 1 (TGF-beta 1) significantly correlated with lymph node metastasis and poor prognosis in patients with gastric carcinoma. Anticancer Res 2000, 20:4489-4493.

40. Lesinski GB, Kondadasala SV, Crespin T, Shen L, Kendra K, Walker M, Caron WE: Multiparametric flow cytometric analysis of inter-patient variation in STAT1 phosphorylation following interferon Alfa immunotherapy. J Natl Canc Inst 2004, 96:1331-1342.

41. Varker KA, Kondadasala SV, Go MR, Lesinski GB, Ghosh-Berkebile R, Lehman A, Monk JP, Olencki T, Kendra K, Caron WE: Multiparametric flow cytometric analysis of signal transducer and activator of transcription 5 phosphorylation in immune cell subsets in vitro and following interleukin-2 immunotherapy. Clin Cancer Res 2006, 12:5850-5858.

42. Kaplan DH, Shankaran V, Dighe AS, Stockert E, Aguet M, Old LJ, Schreiber RD: Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci USA 1998, 95:7556-7561.

43. Meraz MA, White JM, Sheehan KC, Bach EA, Rodig SJ, Dighe AS, Kaplan DH, Riley JK, Greenlund AC, Campbell D, et al: Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway. Cell 1996, 84:421-442.

44. Wang W, Edington HD, Rao UN, Jucik DM, Landr SR, Ferrone S, Kirkwood JM: Modulation of signal transducers and activators of transcription 1 and 3 signaling in melanoma by high-dose IFNalpha2b. Clin Cancer Res 2007, 13:1523-1531.

45. Humpolickova-Adamkova L, Kovarik J, Dusek L, Lauerova B, Boudry V, Fait V, Foltova M, Kreydl T, Kovarik A: Interferon-alpha treatment may negatively influence disease progression in melanoma patients by hyperactivation of STAT3 protein. Eur J Cancer 2009, 45:1315-1323.

46. Clemente CG, Mihm MC, Bufalino R, Zunida S, Collini P, Cascinelli N: Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 1996, 77:1303-1310.

47. Bogunovic D, O'Neill DW, Belitskaya-Lesy V, Vacic V, Yu YL, Adams S, Darvishian F, Berman R, Shapiro R, Pavlick AC, et al: Immune profile and mitotic index of metastatic melanoma lesions enhance clinical staging in predicting patient survival. Proc Natl Acad Sci USA 2009, 106:20249-20243.